Evaluating the Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 in Healthy Female Subjects.
Status:
Completed
Trial end date:
2015-11-13
Target enrollment:
Participant gender:
Summary
This study was a single-center positive-controlled, randomized, dose-escalation study of
HSK3486 in healthy female subjects administered as a single IV bolus dose.Subjects were
confined to the study unit from the evening of Day -1 until the morning of Day 2, then were
required to return for a follow up visit on Day 5. Intensive safety, PD and PK assessments
were performed prior to dosing on Day 1 until 24 hours post-dose (Day 2).
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Haisco Pharmaceutical Group Co., Ltd Sichuan Haisco Pharmaceutical Group Co., Ltd.